Abstract | OBJECTIVE: METHODS: Group A received ethinyl-estradiol 0.03 mg + drospirenone 3 mg (EE + DRSP; n = 56) and Group B received ethinyl-estradiol 0.03 mg + chlormadinone acetate 2 mg (EE + CMA; n = 50). Clinical, hormonal and biochemical parameters were compared at baseline, 6 months, 12 months and 24 months. RESULTS: The increase in total cholesterol and hsCRP levels was statistically significantly higher at 6, 12 and 24 months in Group B when compared with Group A. The change in the high-density lipoprotein cholesterol level at the 24 months of treatment was statistically significantly higher in Group A. Group A has a significantly higher reduction in FAI at 6 and 24 months, in FGS at 6, 12 and 24 months and in HOMA-IR index at 12 and 24 months when compared with Group B. CONCLUSIONS:
|
Authors | Recep Yildizhan, Anik Ilhan Gokce, Begum Yildizhan, Numan Cim |
Journal | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
(Gynecol Endocrinol)
Vol. 31
Issue 5
Pg. 396-400
(May 2015)
ISSN: 1473-0766 [Electronic] England |
PMID | 25739031
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Androstenes
- Blood Glucose
- Cholesterol, HDL
- Cholesterol, LDL
- Contraceptives, Oral, Combined
- Contraceptives, Oral, Synthetic
- Triglycerides
- Chlormadinone Acetate
- Ethinyl Estradiol
- Luteinizing Hormone
- Follicle Stimulating Hormone
- C-Reactive Protein
- drospirenone
|
Topics |
- Adult
- Androstenes
(therapeutic use)
- Blood Glucose
(metabolism)
- Blood Pressure
- C-Reactive Protein
(metabolism)
- Chlormadinone Acetate
(therapeutic use)
- Cholesterol, HDL
(metabolism)
- Cholesterol, LDL
(metabolism)
- Contraceptives, Oral, Combined
(therapeutic use)
- Contraceptives, Oral, Synthetic
(therapeutic use)
- Ethinyl Estradiol
(therapeutic use)
- Female
- Follicle Stimulating Hormone
(metabolism)
- Follow-Up Studies
- Humans
- Insulin Resistance
- Longitudinal Studies
- Luteinizing Hormone
(metabolism)
- Polycystic Ovary Syndrome
(drug therapy, metabolism)
- Treatment Outcome
- Triglycerides
(metabolism)
- Waist-Hip Ratio
- Young Adult
|